British pharma contender GlaxoSmithKline ($GSK) is striving to regain relevance in a field long overshadowed by its rivals ...

In its statement, GSK said the $30 billion investment would include capital investments in its U.S. supply chain and more ...

British Big Pharma GSK is welcoming President Donald Trump to the U.K. with a hefty gift: a five-year, $30 billion planned ...

The pharmaceutical company plans to break ground on a new manufacturing facility in Upper Merion, Pennsylvania, in 2026.

GSK will invest $30 billion in U.S. R&D and manufacturing, including a new biologics factory, AI upgrades, and expanded drug ...

GSK commits $30 billion investment in U.S. R&D and manufacturing during Trump’s UK state visit, strengthening its focus on ...

The new projects, including AI efforts in Pennsylvania and three other states, are part of the British firm's pledge to ...

GSK ( NYSE: GSK) said it is planning to invest at least $30B across the U.S. in research and development and supply chain ...

GSK plans a $30 billion investment in US R&D and manufacturing, including $1.2 billion for advanced facilities and AI ...

The British drugmaker’s commitment comes as some of its pharma peers question their U.K. presence amid a widening row there ...

As President Donald Trump started his state visit to the UK, GSK unveiled a massive $30 billion investment in manufacturing ...